Category: ANNOUNCEMENTS - Page 5 - Start Medical Product Development

Sumbu Unveils World’s First Dual-Vector Consumer Exoskeleton at CES 2026

January 3, 2026

LAS VEGAS, Jan. 3, 2026 /PRNewswire/ — Today at CES 2026, Sumbu announced its Exo-S3 line of dual-vector exoskeletons designed for the general public: the Exo-S3, Exo-S3 Pro and Exo-S3 Ultra. The series is the world’s first commercially available dual-vector exoskeleton designed to support human movement across real-world terrain. This release establishes a new market for lightweight, AI-powered wearable mobility products.

StimLabs Announces FDA Clearance of Theracor

January 2, 2026

Theracor is a sheet device derived from human umbilical cord extracellular matrix (ECM) intended to cover, protect, and provide a moist wound environment

Overture Orthopaedics Announces Milestone $1.0Mn in Sales of its OvertureTi Knee Resurfacing System

December 31, 2025

OvertureTi Knee Resurfacing System implants are designed specifically as an alternative when it is still too early for arthroplasty

Medtech M&A: The biggest deals of 2025

December 30, 2025

In 2025, the medtech industry saw another year full of all kinds of deals in the mergers and acquisitions (M&A) arena.

The largest medtech funding rounds of 2025

December 29, 2025

As another year winds down, it’s safe to say that investment in medtech is not stopping any time soon.

MPM Medical Expands U.S. Manufacturing Capabilities, Acquires FDA 510(k) for Surgical and Advanced Wound Care Collagen

December 16, 2025

New production capacity strengthens MPM Medical’s position as a leading U.S. manufacturer and follows the company’s recent launch of collagen at-home wound care kits

OrthAlign Expands Lantern® Hip Platform to Support Posterior-Based Surgical Approaches in Total Hip Arthroplasty

December 16, 2025

IRVINE, Calif., Dec. 16, 2025 /PRNewswire/ — OrthAlign, Inc., a global leader in surgical navigation technologies, today announced the expansion of its Lantern® Hip platform to include support for posterior-based approaches in total hip arthroplasty (THA).

P&F secures FDA approval for TRICAV II pivotal clinical trial for severe tricuspid regurgitation

December 12, 2025

P&F USA, Inc., the U.S. subsidiary of heart valve manufacturer P&F Products and Features GmbH, today announced that the U.S. Food and Drug Administration (FDA) has approved initiation of the TRICAV II Pivotal Trial.

EyeYon Medical Ltd. Receives FDA IDE Approval to Initiate U.S. Clinical Study of EndoArt®, the First Artificial Endothelial Layer for Corneal Edema

December 8, 2025

NES ZIONA, Israel, Dec. 8, 2025 /PRNewswire/ — EyeYon Medical Ltd., a global leader in ophthalmic innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to initiate a U.S. clinical study of EndoArt®, the world’s first synthetic endothelial layer for the treatment of chronic corneal edema. EndoArt® is currently designated by the FDA as a Breakthrough Device.

SS Innovations submits Mantra surgical robot to FDA for clearance